Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford, MA 01730
June 14, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, NE
Washington, DC 20549
| Attention: | Sonia Bednarowski Justin Dobbie Rolf Sunderwall Jim Rosenberg | |
| Re: | Stoke Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-231700) originally filed May 23, 2019, as amended, and corresponding Registration Statement on Form 8-A (File No. 001-38938) filed June 11, 2019 | |
Requested Date: June 18, 2019
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
Stoke Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Ms. Forbess at (415)-875-2420.
* * *
| Sincerely,
| ||
| STOKE THERAPEUTICS, INC. | ||
| By: | /s/ Stephen J. Tulipano | |
| Stephen J. Tulipano | ||
| Chief Financial Officer | ||
| cc: | Edward M. Kaye, Chief Executive Officer |
Stoke Therapeutics, Inc.
Robert A. Freedman, Esq.
Effie Toshav, Esq.
Julia Forbess, Esq.
Fenwick & West LLP
[Signature Page to Company Acceleration Request Letter]